<p>Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]</p>
نویسندگان
چکیده
منابع مشابه
Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference.
In a recent review, Mathijssen et al. [1] proposed using flatfixed dosing regimens rather than body surface area (BSA)based dosing for anticancer drugs because “it does not seem worse than using BSA-based dosing” with regard to pharmacokinetic variability. We feel that this statement, together with other recent publications arguing against BSAbased dosing, requires a counterpart. Most cytotoxic...
متن کاملTowards better ICU antibiotic dosing.
OBJECTIVE To review the recent pharmacokinetic and pharmacodynamic reports of some of the commonly used antibiotics in critically ill patients and recommend alterations in their administration to improve their efficacy. DATA SOURCES Relevant articles and published reviews on aminoglycoside, third and fourth generation cephalosporins, vancomycin and ciprofloxacin dosing in critically ill patie...
متن کاملDosing Instructions
Michelle Aldrich (left) As VAlerie corrAl of WAMM writes out a dosing regimen for using cannabis oil as a treatment for lung cancer. Aldrich’s remarkable first-person story starts on page 18. continued on page 15 By Fred Gardner Increasing numbers of people have been using Cannabis “oil” —plant extracts consisting of 50% or more THC and/ or CBD— to treat conditions ranging from mild rashes to p...
متن کاملOpioid Dosing Policy: Pharmacological Considerations Regarding Equianalgesic Dosing
Jeffrey Fudin, PharmD, DAIPM, FCCP, FASHP President and Director, Scientific and Clinical Affairs for Remitigate, LLC, Delmar, NY Adjunct Associate Professor of Pharmacy Practice and Pain Management, Albany College of Pharmacy and Health Sciences, Albany, NY Adjunct Associate Professor, Western New England University College of Pharmacy, Springfield, MA Clinical Pharmacy Specialist and Director...
متن کاملAlternative dosing schedules for irinotecan.
Most of the clinical experience with irinotecan (CPT-11 [Camptosar]) has been with either a weekly or an every-3-week schedule. Recent phase I trials have explored new routes and schedules of administration. One approach attempts to maximize dose frequency and intensity by giving irinotecan every 2 weeks. A phase I trial of this approach is now complete and has led to a phase II trial in patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Pharmacology: Advances and Applications
سال: 2020
ISSN: 1179-1438
DOI: 10.2147/cpaa.s282866